Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Peer Christiansen"'
Autor:
Helle Mikel Hvid, Eva Balling, Peer Christiansen, Katrine Rye Hauerslev, Lone Fischer, Tine Engberg Damsgaard, Jens Overgaard
Publikováno v:
Hauerslev, K R, Overgaard, J, Damsgaard, T E, Hvid, H M, Balling, E, Fischer, L & Christiansen, P 2021, ' Oncoplastic breast surgery versus conventional breast conserving surgery-a prospective follow-up study of subjective loco-regional late morbidity ', Acta Oncologica, vol. 60, no. 6, pp. 750-759 . https://doi.org/10.1080/0284186X.2021.1900907
Hauerslev, K R, Overgaard, J, Damsgaard, T E, Hvid, H M, Balling, E, Fischer, L & Christiansen, P 2021, ' Oncoplastic breast surgery versus conventional breast conserving surgery–a prospective follow-up study of subjective loco-regional late morbidity ', Acta Oncologica, vol. 60, no. 6, pp. 750-759 . https://doi.org/10.1080/0284186X.2021.1900907
Hauerslev, K R, Overgaard, J, Damsgaard, T E, Hvid, H M, Balling, E, Fischer, L & Christiansen, P 2021, ' Oncoplastic breast surgery versus conventional breast conserving surgery–a prospective follow-up study of subjective loco-regional late morbidity ', Acta Oncologica, vol. 60, no. 6, pp. 750-759 . https://doi.org/10.1080/0284186X.2021.1900907
Background and aim: Few studies have focused on the symptoms of loco-regional morbidity in shoulders, arms, and breasts related to oncoplastic breast surgery (OPS). This study aimed to determine if a difference exists in the prevalence or variety of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13bee5661c44b6984b9b29770567f62f
https://pure.au.dk/portal/da/publications/oncoplastic-breast-surgery-versus-conventional-breast-conserving-surgery--a-prospective-followup-study-of-subjective-locoregional-late-morbidity(0710f7f2-5139-443a-9c1d-79543958aebb).html
https://pure.au.dk/portal/da/publications/oncoplastic-breast-surgery-versus-conventional-breast-conserving-surgery--a-prospective-followup-study-of-subjective-locoregional-late-morbidity(0710f7f2-5139-443a-9c1d-79543958aebb).html
Autor:
Trine Tramm, Stephen Hamilton-Dutoit, James W. Baurley, Kristina Lystlund Lauridsen, Per Damkier, Anders Kjærsgaard, Peer Christiansen, Lindsay J Collin, Kristina B. Christensen, Maret L. Maliniak, Rebecca A. Silliman, Deirdre Cronin-Fenton, Timothy L. Lash, Michael E. Zwick, Thomas P. Ahern, Bent Ejlertsen, R. Benjamin Isett, Rebecca Nash, Henrik Toft Sørensen
Publikováno v:
Ahern, T P, Collin, L J, Baurley, J W, Kjærsgaard, A, Nash, R, Maliniak, M L, Damkier, P, Zwick, M E, Isett, R B, Christiansen, P M, Ejlertsen, B, Lauridsen, K L, Christensen, K, Silliman, R A, Toft Sørensen, H, Tramm, T, Hamilton-Dutoit, S, Lash, T L & Cronin-Fenton, D 2020, ' Metabolic Pathway Analysis and Effectiveness of Tamoxifen in Danish Breast Cancer Patients ', Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, vol. 29, no. 3, pp. 582-590 . https://doi.org/10.1158/1055-9965.EPI-19-0833
Ahern, T P, Collin, L J, Baurley, J W, Kjærsgaard, A, Nash, R, Maliniak, M L, Damkier, P, Zwick, M E, Isett, R B, Christiansen, P M, Ejlertsen, B, Lauridsen, K L, Christensen, K B, Silliman, R A, Toft Sorensen, H, Tramm, T, Hamilton-Dutoit, S, Lash, T L & Cronin Fenton, D 2020, ' Metabolic pathway analysis and effectiveness of tamoxifen in Danish breast cancer patients ', Cancer Epidemiology, Biomarkers & Prevention, vol. 29, no. 3, pp. 582-590 . https://doi.org/10.1158/1055-9965.EPI-19-0833
Cancer Epidemiol Biomarkers Prev
Ahern, T P, Collin, L J, Baurley, J W, Kjærsgaard, A, Nash, R, Maliniak, M L, Damkier, P, Zwick, M E, Isett, R B, Christiansen, P M, Ejlertsen, B, Lauridsen, K L, Christensen, K B, Silliman, R A, Toft Sorensen, H, Tramm, T, Hamilton-Dutoit, S, Lash, T L & Cronin Fenton, D 2020, ' Metabolic pathway analysis and effectiveness of tamoxifen in Danish breast cancer patients ', Cancer Epidemiology, Biomarkers & Prevention, vol. 29, no. 3, pp. 582-590 . https://doi.org/10.1158/1055-9965.EPI-19-0833
Cancer Epidemiol Biomarkers Prev
Background: Tamoxifen and its metabolites compete with estrogen to occupy the estrogen receptor. The conventional dose of adjuvant tamoxifen overwhelms estrogen in this competition, reducing breast cancer recurrence risk by nearly half. Phase I metab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1801d69fb5cd7b94c2ec62c58bf25321
https://findresearcher.sdu.dk:8443/ws/files/162520147/1055_9965.EPI_19_0833.full.pdf
https://findresearcher.sdu.dk:8443/ws/files/162520147/1055_9965.EPI_19_0833.full.pdf
Autor:
Sinna Pilgaard Ulrichsen, Henrik Toft Sørensen, Lauren E. McCullough, Michael Goodman, Kristina B. Christensen, Kristina Lystlund Lauridsen, Per Damkier, Rami Yacoub, Lance A. Waller, Timothy L. Lash, Thomas P. Ahern, Bent Ejlertsen, Deirdre Cronin-Fenton, Peer Christiansen, Lindsay J Collin, Stephen Hamilton-Dutoit
Publikováno v:
Collin, L J, Ulrichsen, S P, Ahern, T P, Goodman, M, McCullough, L E, Waller, L A, Bang Christensen, K, Damkier, P, Hamilton-Dutoit, S, Lauridsen, K L, Yacoub, R, Christiansen, P M, Ejlertsen, B, Sørensen, H T, Cronin-Fenton, D P & Lash, T L 2020, ' 17β-Hydroxysteroid dehydrogenase 1:2 and breast cancer recurrence : a Danish population-based study ', Acta Oncologica, vol. 59, no. 3, pp. 329-333 . https://doi.org/10.1080/0284186X.2019.1684560
Acta Oncol
Acta Oncol
BACKGROUND: Approximately 20–40% of patients diagnosed with breast cancer will experience a recurrence up to 20 years after their original diagnosis. 17?-hydroxysteroid dehydrogenase 1 and 2 (HSD17B1 and HSD17B2, respectively) regulate intratumoral
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b1221ea8ab1bf3d1024c9bb6d4f0751
https://portal.findresearcher.sdu.dk/da/publications/2ac08303-0b6f-4061-acbe-e409048b9d9c
https://portal.findresearcher.sdu.dk/da/publications/2ac08303-0b6f-4061-acbe-e409048b9d9c
Publikováno v:
Zøylner, I A, Lomborg, K, Christiansen, P M & Kirkegaard, P 2019, ' Surgical breast cancer patient pathway : Experiences of patients and relatives and their unmet needs ' Health Expectations, vol. 22, no. 2, pp. 262-272 . https://doi.org/10.1111/hex.12869
Health Expectations : An International Journal of Public Participation in Health Care and Health Policy
Zøylner, I A, Lomborg, K, Christiansen, P M & Kirkegaard, P 2019, ' Surgical breast cancer patient pathway : Experiences of patients and relatives and their unmet needs ', Health Expectations, vol. 22, no. 2, pp. 262-272 . https://doi.org/10.1111/hex.12869
Health Expectations : An International Journal of Public Participation in Health Care and Health Policy
Zøylner, I A, Lomborg, K, Christiansen, P M & Kirkegaard, P 2019, ' Surgical breast cancer patient pathway : Experiences of patients and relatives and their unmet needs ', Health Expectations, vol. 22, no. 2, pp. 262-272 . https://doi.org/10.1111/hex.12869
BACKGROUND AND AIM: Breast cancer is the most common cancer disease in women worldwide. In Denmark, the law prescribes cancer patient pathways (CPPs) in general and thus also for breast cancer. Although results from patient satisfaction surveys show
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ce3059ce853c6e37c1cd9389c5af268
https://pure.au.dk/portal/da/publications/surgical-breast-cancer-patient-pathway(d353a060-a6cf-4891-ab29-e63cb0c22431).html
https://pure.au.dk/portal/da/publications/surgical-breast-cancer-patient-pathway(d353a060-a6cf-4891-ab29-e63cb0c22431).html
Autor:
Trine Tramm, Peer Christiansen, Anne Bodilsen, Hanne Melgaard Nielsen, Jonas Amstrup Funder, Anne Schmidt Sorensen, Marco Mele, Josephine Bruun
Publikováno v:
Mele, M, Sørensen, A S, Bruun, J, Funder, J A, Tramm, T, Bodilsen, A, Nielsen, H M & Christiansen, P M 2019, ' Inflammatory breast cancer : A review from our experience ', Breast Disease, vol. 38, no. 2, pp. 47-55 . https://doi.org/10.3233/BD-180365
INTRODUCTION: Inflammatory Breast Cancer (IBC) is a distinct and rare type of breast cancer accounting for up to 6% of all breast cancer cases in Europe. The aim of this study was to investigate diagnostic methods, treatments, and outcome after IBC i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c2fde238c6e05cc881054e1f438ab79
https://pure.au.dk/portal/da/publications/inflammatory-breast-cancer(c3af6599-1a4d-4e37-8e81-962726ba1a64).html
https://pure.au.dk/portal/da/publications/inflammatory-breast-cancer(c3af6599-1a4d-4e37-8e81-962726ba1a64).html
Autor:
Per Damkier, Thomas P. Ahern, Stephen Hamilton-Dutoit, Anders Kjærsgaard, Lindsay J Collin, Peer Christiansen, Kristina B. Christensen, Deirdre Cronin-Fenton, Kristina Lystlund Lauridsen, Timothy L. Lash, Henrik Toft Sørensen, Rami Yacoub
Publikováno v:
Collin, L J, Cronin-Fenton, D P, Ahern, T P, Christensen, K B, Damkier, P, Hamilton-Dutoit, S, Kjaersgaard, A, Lauridsen, K L, Yacoub, R, Christiansen, P, Sørensen, H T & Lash, T L 2019, ' Expression of survivin does not appear to influence breast cancer recurrence risk ', Acta Oncologica, vol. 58, no. 2, pp. 154-161 . https://doi.org/10.1080/0284186X.2018.1503419
BACKGROUND: Survivin is an inhibitor of apoptosis, and its expression associates with poor outcomes in multiple cancers. It may be a therapeutic target due to its unique expression in cancer cells.METHODS: We estimated the association between nuclear
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11c5d4567c22bdcc224bb419fa7029e9
https://pure.au.dk/portal/da/publications/expression-of-survivin-does-not-appear-to-influence-breast-cancer-recurrence-risk(8edf1125-b428-4628-b8be-a770a766d5de).html
https://pure.au.dk/portal/da/publications/expression-of-survivin-does-not-appear-to-influence-breast-cancer-recurrence-risk(8edf1125-b428-4628-b8be-a770a766d5de).html
Autor:
Maj-Britt Jensen, Bo Grundtmann, Peer Christiansen, Anne Vibeke Lænkholm, Tove Filtenborg Tvedskov, Ann Knoop, Signe Korsgaard Skriver, Birgitte Bruun Rasmussen, Jürgen Handler, Bent Ejlertsen
Publikováno v:
Skriver, S K, Laenkholm, A-V, Rasmussen, B B, Handler, J, Grundtmann, B, Tvedskov, T F, Christiansen, P, Knoop, A S, Jensen, M-B & Ejlertsen, B 2018, ' Neoadjuvant letrozole for postmenopausal estrogen receptor-positive, HER2-negative breast cancer patients, a study from the Danish Breast Cancer Cooperative Group (DBCG) ', Acta Oncologica, vol. 57, pp. 1-7 . https://doi.org/10.1080/0284186X.2017.1401228
INTRODUCTION: Neoadjuvant endocrine treatment (NET) is a low-toxicity approach to achieve operability in locally advanced breast cancer, and to facilitate breast conservation in early breast cancer, particular in patients with highly estrogen recepto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04cf3ecf5be74027a71b12f95d3263aa
https://pure.au.dk/portal/da/publications/neoadjuvant-letrozole-for-postmenopausal-estrogen-receptorpositive-her2negative-breast-cancer-patients-a-study-from-the-danish-breast-cancer-cooperative-group-dbcg(00e87aba-9155-43c4-aa58-bd0b14890dc5).html
https://pure.au.dk/portal/da/publications/neoadjuvant-letrozole-for-postmenopausal-estrogen-receptorpositive-her2negative-breast-cancer-patients-a-study-from-the-danish-breast-cancer-cooperative-group-dbcg(00e87aba-9155-43c4-aa58-bd0b14890dc5).html
Autor:
Jens Overgaard, Peer Christiansen, Henning T. Mouridsen, Bent Ejlertsen, Niels Kroman, Ann Søgaard Knoop, Birgitte Vrou Offersen, Maj-Britt Jensen
Publikováno v:
Ejlertsen, B, Offersen, B V, Overgaard, J, Christiansen, P, Jensen, M-B, Kroman, N, Knoop, A S & Mouridsen, H 2018, ' Forty years of landmark trials undertaken by the Danish Breast Cancer Cooperative Group (DBCG) nationwide or in international collaboration ', Acta Oncologica, vol. 57, no. 1, pp. 3-12 . https://doi.org/10.1080/0284186X.2017.1408962
BACKGROUND:Over the past 40 years the Danish Breast Cancer Cooperative Group (DBCG) has made significant contributions to improve outcome and to make treatment of patients with early breast cancer more tolerable through nationwide and international t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7d730a12aeb410ae614cdd12ea42e98
https://pure.au.dk/portal/da/publications/forty-years-of-landmark-trials-undertaken-by-the-danish-breast-cancer-cooperative-group-dbcg-nationwide-or-in-international-collaboration(4aa444ed-ea98-4786-84e7-e4fe620f675e).html
https://pure.au.dk/portal/da/publications/forty-years-of-landmark-trials-undertaken-by-the-danish-breast-cancer-cooperative-group-dbcg-nationwide-or-in-international-collaboration(4aa444ed-ea98-4786-84e7-e4fe620f675e).html
Autor:
Peer Christiansen, Anne Vibeke Lænkholm, Maj-Britt Jensen, Bent Ejlertsen, Henning T. Mouridsen, Birgitte Vrou Offersen, Niels Kroman
Publikováno v:
Jensen, M-B, Laenkholm, A-V, Offersen, B V, Christiansen, P, Kroman, N, Mouridsen, H T & Ejlertsen, B 2018, ' The clinical database and implementation of treatment guidelines by the Danish Breast Cancer Cooperative Group in 2007-2016 ', Acta Oncologica, vol. 57, no. 1, pp. 13-18 . https://doi.org/10.1080/0284186X.2017.1404638
BACKGROUND:Since 40 years, Danish Breast Cancer Cooperative Group (DBCG) has provided comprehensive guidelines for diagnosis and treatment of breast cancer. This population-based analysis aimed to describe the plurality of modifications introduced ov
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be4495310fe193d81c6b2686b947c3a2
https://pure.au.dk/portal/da/publications/the-clinical-database-and-implementation-of-treatment-guidelines-by-the-danish-breast-cancer-cooperative-group-in-20072016(d4dd5b59-92ee-403d-8beb-ab52f91f919a).html
https://pure.au.dk/portal/da/publications/the-clinical-database-and-implementation-of-treatment-guidelines-by-the-danish-breast-cancer-cooperative-group-in-20072016(d4dd5b59-92ee-403d-8beb-ab52f91f919a).html
Autor:
Per Damkier, Timothy L. Lash, Thomas P. Ahern, Henrik Toft Sørensen, Deirdre Cronin-Fenton, Bent Ejlertsen, Peer Christiansen
Publikováno v:
Cronin-Fenton, D, Lash, T L, Ahern, T P, Damkier, P, Christiansen, P, Ejlertsen, B & Sørensen, H T 2018, ' Concurrent new drug prescriptions and prognosis of early breast cancer : studies using the Danish Breast Cancer Group clinical database ', Acta Oncologica, vol. 57, no. 1, pp. 1-9 . https://doi.org/10.1080/0284186X.2017.1407040
BACKGROUND: Myriad reports suggest that frequently used prescription drugs alter the viability of breast cancer cells in pre-clinical studies. Routine use of these drugs, therefore, may impact breast cancer prognosis, and could have important implica